Prognostic impact of Ki-67 proliferative index in resectable pancreatic ductal adenocarcinoma

I. Pergolini1, S. Crippa3, M. Pagnanelli3, G. Belfiori1, A. Pucci1, S. Partelli3, C. Rubini2, P. Castelli4, G. Zamboni4,5 and M. Falconi3

Departments of 1Surgery and 2Pathology, Università Politecnica delle Marche, Ospedali Riuniti, Ancona, 3Pancreatic Surgery Unit, Pancreas Translational and Clinical Research Center, Università Vita e Salute, IRCCS San Raffaele Scientific Institute, Milan, 4Department of Pathology, Ospedale Sacro Cuore – Don Calabria, Negrar, and 5Department of Pathology, Università di Verona, Verona, Italy

Correspondence to: Professor M. Falconi, Department of Surgery, Division of Pancreatic Surgery, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy (e-mail: falconi.massimo@hsr.it)

Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease characterized by complex biological features and poor prognosis. A prognostic stratification of PDAC would help to improve patient management. The aim of this study was to analyse the expression of Ki-67 in relation to prognosis in a cohort of patients with PDAC who had surgical treatment.

Methods: Patients who had pancreatic resection between August 2010 and October 2014 for PDAC at two Italian centres were reviewed retrospectively. Patients with metastatic or locally advanced disease, those who received neoadjuvant chemotherapy, patients with PDAC arising from intraductal papillary mucinous neoplasm and those with missing data were excluded. Clinical and pathological data were retrieved and analysed. Ki-67 expression was evaluated using immunohistochemistry and patients were stratified into three subgroups. Survival analyses were performed for disease-free (DFS) and disease-specific (DSS) survival outcomes according to Ki-67 expression and tumour grading.

Results: A total of 170 patients met the selection criteria. Ki-67 expression of 10 per cent or less, 11–50 per cent and more than 50 per cent significantly correlated with DFS and DSS outcomes ($P = 0.016$ and $P = 0.002$ respectively). Ki-67 index was an independent predictor of poor DFS (hazard ratio (HR) $0.52$, 95 per cent c.i. $0.29$ to $0.91$; $P = 0.022$) and DSS (HR $0.53$, $0.31$ to $0.91$; $P = 0.022$). Moreover, Ki-67 index correlated strongly with tumour grade ($P < 0.001$). Patients with PDAC classified as a G3 tumour with a Ki-67 index above 50 per cent had poor survival outcomes compared with other patients ($P < 0.001$ for both DFS and DSS).

Conclusion: Ki-67 index could be of use in predicting the survival of patients with PDAC. Further investigation in larger cohorts is needed to validate these results.

Presented as a poster to Pancreas 2018, Baltimore, Maryland, USA, April 2018, and to the European Pancreatic Club, Berlin, Germany, June 2018; published in abstract form as Pancreatology 2018; 18: S84

Funding information
No funding

Paper accepted 26 March 2019
Published online 10 May 2019 in Wiley Online Library (www.bjsopen.com). DOI: 10.1002/bjs5.50175

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease characterized by complex biological features and a poor prognosis1,2. Recent literature3–5 in this field has focused on molecular biomarkers and targets to improve staging, treatment and, consequently, patient survival.

The expression of Ki-67 in tumour tissue is a well known marker associated with tumour proliferation and correlated with the progression, risk of metastasis and prognosis of several tumours, including breast and prostate cancers6–10. In pancreatic neuroendocrine neoplasms (PanNENs), Ki-67 has been documented to play an essential role in defining tumour grading and classification (WHO 2017/ENETS criteria), and is recognized as an independent predictor of survival11–16. Moreover, some authors17–20 have reported that the Ki-67 index could be determined from selected PanNEN samples
obtained by endoscopic ultrasonography–fine-needle aspiration (EUS–FNA), thereby demonstrating its value in the preoperative phase. In PDAC, the prognostic value of Ki-67 has not yet been established. The aim of this study was to analyse the expression of Ki-67 as a prognostic factor in a cohort of patients with resected PDAC, in relation to survival outcomes.

Methods

This study was designed according to the REMARK and STROBE guidelines. It was not preregistered with an analysis plan in an independent institutional registry.

Patients who had a pancreatic resection for histologically confirmed PDAC between August 2010 and October 2014 at the Ospedale Sacro Cuore – Don Calabria (Negra, Verona, Italy), a teaching hospital affiliated to the University of Verona, and at the Ospedali Riuniti Ancona Università Politecnica delle Marche (Ancona, Italy), a university hospital and referral centre for hepatobilipancreatic surgery in the Marche Region, were reviewed retrospectively. Surgical resections were performed in both centres by the same surgeons. Both institutions were documented as high-volume centres for pancreatic surgery (more than 100 pancreatic resections annually) at the time of the study.

Patients with metastatic or locally advanced disease, those who had received neoadjuvant chemotherapy, patients with PDAC arising from intraductal papillary mucinous neoplasms, and patients with missing data or follow-up were excluded. Written informed consent for use of their personal data and tissue for research purposes was obtained from all patients included in the study. Institutional review board approval was not required owing to the retrospective nature of the study.

Data on patient demographics, clinical presentation, tumour marker levels (serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA)), preoperative treatments, surgical and postoperative data, including delivery of adjuvant treatment, were recorded. The absence of jaundice, the preoperative concentration of CA19-9 was recorded; in patients with abnormal serum bilirubin values at the time of diagnosis, the CA19-9 level was determined after biliary drainage and jaundice resolution. Pathology data included tumour size and grade, number of resected/positive lymph nodes, TNM staging, lymphatic and vascular invasion, perineural invasion and margin status. Glandular differentiation and mitotic activity were evaluated in the entire tumour specimen and the more severe grades were recorded. TNM staging was done in accordance with the 7th AJCC system, and margin status was determined according to the 2010 WHO definition.

Table 1 Details of patients who had upfront surgery

| No. of patients* | (n = 170) |
|------------------|----------|
| Age (years)†     | 70 (44–85) |
| Sex ratio (M : F) | 92 : 78 |
| Preoperative tumour marker levels† | |
| CEA (ng/ml)      | 2 (0–90) |
| CA19-9 (units/ml)| 36 (0–2689) |
| Jaundice at diagnosis | 113 (66.5) |
| Duration of surgery (min)† | 343 (120–575) |
| Postoperative complications | 86 (50.6) |
| Pancreatic fistula | 46 (27.1) |
| Biliary fistula | 12 (7.1) |
| Duration of hospital stay (days)† | 11 (5–70) |
| Readmission | 50 (29.4) |
| Ki-67 index (%)† | 30 (2–95) |
| ≤ 10 | 43 (25.3) |
| 11–50 | 106 (62.4) |
| > 50 | 21 (12.4) |
| Tumour size (mm)† | 25 (2–70) |
| Grade of differentiation | |
| G1 | 15 (8.8) |
| G2 | 86 (50.6) |
| G3 | 69 (40.6) |
| T category | |
| T1 | 12 (7.1) |
| T2 | 10 (5.9) |
| T3 | 148 (87.1) |
| T4 | 0 (0) |
| N category | |
| N0 | 48 (28.2) |
| N1 | 122 (71.8) |
| Resection margin | |
| R0 | 120 (70.6) |
| R+ | 50 (29.4) |
| Lymphatic invasion | 126 (74.1) |
| Vascular invasion | 115 (67.6) |
| Perineural invasion | 145 (85.3) |
| Stage | |
| Ia | 7 (4.1) |
| Ib | 2 (1.2) |
| Ila | 38 (22.4) |
| Iib | 123 (72.4) |
| Adjuvant treatment | 166 (97.6) |
| Recurrence | 135 (79.4) |
| Died | |
| Yes, from other cause | 6 (3.5) |
| Yes, from pancreatic cancer progression | 109 (64.1) |

*With percentages in parentheses unless indicated otherwise; †values are median (range). CEA, carcinoembryonic antigen; CA, carbohydrate antigen.
**Ki-67 expression**

Formalin-fixed specimens were processed into paraffin according to standard practice. Sections (5 μm) were stained with haematoxylin and eosin for conventional histological examination, and used for Ki-67 immunohistochemical analysis. For Ki-67 immunohistochemical staining, after deparaffinization in xylene for 30–40 min, the specimen slides were rehydrated in a descending alcohol series, from absolute ethanol to distilled water. Before staining, in order to retrieve antigen epitopes, the samples were heated in an aqueous sodium citrate solution in a microwave oven (temperature 98°C, pH 6) for 20 min. After microwave treatment, the sections were cooled down for a further 20 min. Endogenous peroxidase was blocked by 0.3% hydrogen peroxide for 7 min. After washing in Tris-buffered saline (TBS), the slides were incubated at room temperature for 30 min with the primary antibody for Ki-67. The primary antibody was a monoclonal mouse antihuman Ki-67 antigen (MIB-1; Dako, Glostrup, Denmark) used at a dilution of 1:80. After incubation, the primary antibody was washed away with TBS. The slides were then incubated at room temperature for 20 min, using the visualization system EnVision™ FLEX/HRP (Dako) containing the secondary antimouse/rabbit antibody. Final staining was done with diaminobenzidine tetrahydrochloride (DAB) solution for 10 min at room temperature. Slides were then transferred through an ascending ethanol series, finally through xylene, and then mounted.

Two tissue blocks for each patient were selected from the most representative area of the tumour (the region of the tumour with highest grade). A section of each block was immunolabelled for Ki-67 using the above protocol. Counting of tumour cells was done manually using a Nikon Eclipse 80i microscope (Nikon Instruments, Amsterdam, the Netherlands), at 40× magnification. A counting protocol of 1000 cells was chosen to overcome the marked cellular heterogeneity for each carcinoma, as the number of high-power fields could be variable. The percentage of Ki-67-positive cells was determined by scoring a minimum of 1000 cells within a hotspot area (defined as the area in which the 1000-cell count provided the highest percentage of Ki-67-positive nuclei). Of note, the Ki-67 index was counted in hotspot areas that did not necessarily parallel the histological grade field by field.

**Outcome measure**

Primary outcome measures were disease-free survival (DFS), the first recurrence of cancer after surgery, and disease-specific survival (DSS), death from the disease.
|                                      | Univariable analysis | Multivariable analysis |
|--------------------------------------|----------------------|------------------------|
|                                      | n        | Median DFS (months) | P   | Hazard ratio | P   |
| Age (years)                          |          |                    |     |              |     |
| ≤ 70                                 | 93       | 20                  | 0.101 |            |     |
| > 70                                 | 77       |                     | 0.821 |            |     |
| Sex                                  |          |                    |     |              |     |
| M                                    | 92       |                     | 0.665 |            |     |
| F                                    | 78       |                     | 0.001 | 0.52 (0.29, 0.91) | 0.022 |
| Jaundice                             |          |                    |     |              |     |
| No                                   | 57       | 19                  | 0.052 |            |     |
| Yes                                  | 113      |                     | 0.562 |            |     |
| Preoperative CA19-9 (units/ml)       |          |                    |     |              |     |
| ≤ 200                                | 135      | 17                  | 0.016 | 0.52 (0.29, 0.91) | 0.022 |
| > 200                                | 35       |                     | 0.001 |            |     |
| Preoperative CEA (ng/ml)             |          |                    |     |              |     |
| ≤ 2                                  | 109      | 18                  | 0.783 |            |     |
| > 2                                  | 61       |                     | 0.756 |            |     |
| Postoperative complications          |          |                    |     |              |     |
| No                                   | 84       | 20                  | 0.039 | 0.77 (0.54, 1.12) | 0.169 |
| Yes                                  | 86       |                     | 0.732 |            |     |
| Ki-67 index (%)                      |          |                    |     |              |     |
| ≤ 10                                 | 43       | 24                  | 0.001 | 2.28 (1.48, 3.53) | 0.001 |
| 11–50                                | 106      | 18                  | < 0.001 |            |     |
| > 50                                 | 21       | 8                   | < 0.001 |            |     |
| Tumour size (mm)                     |          |                    |     |              |     |
| ≤ 25                                 | 98       | 19                  | 0.026 | 1.55 (1.06, 2.28) | 0.024 |
| > 25                                 | 72       |                     | 0.756 |            |     |
| Grade of differentiation             |          |                    |     |              |     |
| G1                                   | 15       | 29                  | 0.452 |            |     |
| G2                                   | 86       |                     | 0.001 |            |     |
| G3                                   | 69       |                     | 0.123 |            |     |
| T category                           |          |                    |     |              |     |
| T1–2                                 | 22       | 20                  | 0.001 |            |     |
| T3                                   | 148      | 19                  | < 0.001 |            |     |
| N category                           |          |                    |     |              |     |
| N0                                   | 48       | 26                  | 0.001 |            |     |
| N1                                   | 122      | 16                  | < 0.001 |            |     |
| Margin status                        |          |                    |     |              |     |
| R0                                   | 120      | 20                  | 0.026 | 1.55 (1.06, 2.28) | 0.024 |
| R+                                   | 50       |                     | 0.756 |            |     |
| Vascular invasion                    |          |                    |     |              |     |
| No                                   | 55       | 19                  | 0.452 |            |     |
| Yes                                  | 115      |                     | 0.001 |            |     |
| Perineural invasion                  |          |                    |     |              |     |
| No                                   | 25       | 19                  | < 0.001 |            |     |
| Yes                                  | 145      |                     | < 0.001 |            |     |
| Stage                                |          |                    |     |              |     |
| Ia, Ib, Ila                          | 47       | 29                  | 0.001 |            |     |
| IIb                                  | 123      | 16                  |     |              |     |
| Adjuvant treatment                   |          |                    |     |              |     |
| No                                   | 4        | 26                  | 0.842 |            |     |
| Yes                                  | 166      | 19                  |     |              |     |

Values in parentheses are 95 per cent confidence intervals. DFS, disease-free survival; CA, carbohydrate antigen; CEA, carcinoembryonic antigen.
### Table 3: Univariable and multivariable analyses of predictors of disease-specific survival

| Predictor                              | Univariable analysis | Multivariable analysis |
|----------------------------------------|----------------------|------------------------|
|                                        | n        | Median DSS (months) | P     | Hazard ratio | P     |
| Age (years)                            |          |                   |       |              |       |
| ≤ 70                                   | 93       | 33                 | 0.573 |              |       |
| > 70                                   | 77       | 35                 |       |              |       |
| Sex                                    |          |                   |       |              |       |
| M                                      | 92       | 35                 | 0.705 |              |       |
| F                                      | 78       | 34                 |       |              |       |
| Jaundice                               |          |                   |       |              |       |
| No                                     | 57       | 32                 | 0.597 |              |       |
| Yes                                    | 113      | 35                 |       |              |       |
| Preoperative CA19-9 (units/ml)         |          |                   |       |              |       |
| ≤ 200                                  | 135      | 33                 | 0.344 |              |       |
| > 200                                  | 35       | 37                 |       |              |       |
| Preoperative CEA (ng/ml)               |          |                   |       |              |       |
| ≤ 2                                    | 109      | 33                 | 0.626 |              |       |
| > 2                                    | 61       | 36                 |       |              |       |
| Postoperative complications            |          |                   |       |              |       |
| No                                     | 84       | 36                 | 0.918 |              |       |
| Yes                                    | 86       | 34                 |       |              |       |
| Ki-67 index (%)                        |          |                   |       |              |       |
| ≤ 10                                   | 43       | 47                 | 0.002 | 0.53 (0.31, 0.91) | 0.022 |
| 11–50                                  | 106      | 33                 |       |              |       |
| > 50                                   | 21       | 14                 |       |              |       |
| Tumour size (mm)                       |          |                   |       |              |       |
| ≤ 25                                   | 98       | 35                 | 0.697 |              |       |
| > 25                                   | 72       | 33                 |       |              |       |
| Grade of differentiation               |          |                   |       |              |       |
| G1                                     | 15       | n.r.               | 0.001 | 0.63 (0.43, 0.94) | 0.022 |
| G2                                     | 86       | 38                 |       |              |       |
| G3                                     | 69       | 25                 |       |              |       |
| T category                             |          |                   | 0.106 |              |       |
| T1–2                                   | 22       | 56                 |       |              |       |
| T3                                     | 148      | 33                 |       |              |       |
| N category                             |          |                   |       |              |       |
| N0                                     | 48       | n.r.               | <0.001 | 3.37 (1.42, 9.94) | 0.001 |
| N1                                     | 122      | 30                 |       |              |       |
| Margin status                          |          |                   | 0.003 | 1.93 (1.28, 2.89) | 0.002 |
| R0                                     | 120      | 41                 |       |              |       |
| R+                                     | 50       | 27                 |       |              |       |
| Vascular invasion                      |          |                   | 0.337 |              |       |
| No                                     | 55       | 34                 |       |              |       |
| Yes                                    | 115      | 35                 |       |              |       |
| Perineural invasion                    |          |                   | 0.128 |              |       |
| No                                     | 25       | 66                 |       |              |       |
| Yes                                    | 145      | 33                 |       |              |       |
| Stage                                  |          |                   | <0.001 |              |       |
| Ia, Ib, Ila                            | 47       | n.r.               |       |              |       |
| IIb                                    | 123      | 30                 |       |              |       |
| Adjuvant treatment                     |          |                   | 0.406 |              |       |
| No                                     | 4        | 56                 |       |              |       |
| Yes                                    | 166      | 34                 |       |              |       |

Values in parentheses are 95 per cent confidence intervals. DSS, disease-specific survival; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; n.r., not reached.

© 2019 The Authors. www.bjsopen.com BJS Open 2019; 3: 646–655
Follow-up was done on a regular basis by clinical evaluation or telephone interview, and patients were censored at the last available contact date.

**Statistical analysis**

Continuous variables are reported as median (range) values, and categorical variables as numbers with percentages. Continuous variables were dichotomized around the median value, except for CA19-9, for which a cut-off value of 200 units/ml or more was previously documented to correlate with tumour burden, spread and early recurrence after resection of PDAC. Student's t test was used to compare normally distributed continuous variables; non-parametric analyses included Mann–Whitney U and Kruskal–Wallis tests. Survival analysis was done with the Kaplan–Meier method and log rank test using the following Ki-67 cut-off values: 10, 20, 30, 40, 50 and 60 per cent, tertiles and quartiles. Patients were also stratified according to Ki-67 index and tumour grades, and survivals were calculated accordingly.
Multivariable analysis was performed using the Cox regression model to evaluate significant predictors of DFS and DSS. Significant variables in the univariable analysis were included as co-variables; \( P \leq 0.050 \) was considered significant. Statistical analyses were performed in SPSS® version 22.0 for Windows® (IBM, Armonk, New York, USA).

**Results**

Of 272 patients who underwent resection for PDAC during the study period, 170 met the selection criteria (Fig. S1, supporting information).

Patient characteristics, surgical and pathological data are presented in Table 1. PDACs were poorly differentiated (grade G3) in 40-6 per cent of patients, assessed as having T3 status in 87-1 per cent, with lymph node metastasis in 71-8 per cent of the cohort. Lymphatic invasion was documented in 100 per cent of the tumours with a positive N status, but was present in only 8 per cent (4 of 48) of N0 tumours. Some 67-6 per cent of tumours showed microvascular invasion and 85-3 per cent had perineural invasion. Stage IIIb tumours were found in 72-4 per cent of patients. The median Ki-67 index was of 30 (range 2–95) per cent.

**Survival outcomes**

Median follow-up was 32 (range 0–76) months. Some 135 patients (79-4 per cent) had a recurrence. Median DFS was 19 (i.q.r. 35–10) months, and median DSS was 35 (not reached to 21) months. Ki-67 expression of 10 and 50 per cent were the only cut-off values significantly associated with DFS and DSS. On this basis, survival analysis was determined using the following Ki-67 intervals: 10 per cent or less, 11–50 per cent and more than 50 per cent. Median DFS was 24, 18 and 8 months for these respective Ki-67 index values (\( P = 0.016 \) (Fig. 1a and Table 2). Cox regression analysis showed that Ki-67 index (hazard ratio (HR) 0.52, 95 per cent c.i. 0.29 to 0.91; \( P = 0.022 \)), N status (HR 2.28, 1.48 to 3.53; \( P < 0.001 \)) and resection margin status (HR 1.55, 1.06, 2.28; \( P = 0.024 \)) were independent predictors of DFS (Table 2).

DSS decreased significantly in the 10 per cent or less, 11–50 per cent and more than 50 per cent subgroups (47
versus 33 versus 14 months respectively; \( P = 0.002 \) (Fig. 1b; Table 3). Cox regression analysis identified Ki-67 index (HR 0.53, 95 per cent c.i. 0.31 to 0.91; \( P = 0.022 \)), tumour grade (HR 0.63, 0.43 to 0.94; \( P = 0.022 \)), N status (HR 3.37, 1.42 to 3.94; \( P = 0.001 \)) and resection margin status (HR 1.93, 1.28 to 2.89; \( P = 0.002 \)) as independent predictors of DSS (Table 3).

Stage and lymphatic invasion were not considered in the Cox regression analysis because of the overlap with N status.

**Ki-67 and grading**

Median Ki-67 was significantly higher in G3 tumours (Fig. 2). Tumours with a Ki-67 index above 50 per cent showed more aggressive grading: 62 per cent (13 of 21) had a pathological grade consistent with G3, whereas none was assessed as G1. By contrast, G3 tumours showed a more heterogeneous Ki-67 expression (Fig. S2, supporting information). In patients with G3 tumours, a Ki-67 index above 50 per cent was associated with significantly worse median survival than a Ki-67 index of 50 per cent or less (DFS: 7 versus 15 months respectively, \( P = 0.035 \); DSS: 13 versus 29 months, \( P = 0.038 \)). There was no association between Ki-67 index and other pathological parameters, including T status, N status, tumour size, vascular or perineural invasion.

Patients were categorized into three subgroups: patients with G1 tumours with a Ki-67 index of 10 per cent or less (group 1); patients with G3 tumours with a Ki-67 index above 50 per cent (group 2); all other patients (those with G1 tumours with a Ki-67 index above 10 per cent, G2 tumours with any Ki-67 index value and G3 tumours with a Ki-67 index of 50 per cent or less) (group 3) (Fig. 3). Patients in group 2 had poor median survival outcomes compared with those in groups 1 and 3 (DFS: 7 months versus median survival not reached versus 19 months respectively, \( P < 0.001 \); DSS: 13 months versus median survival not reached versus 35 months, \( P < 0.001 \)) (Fig. 4).

**Discussion**

Surgical resection followed by adjuvant chemotherapy/chemoradiotherapy is considered the standard of care for localized and resectable pancreatic cancer; however, the majority of patients develop tumour recurrence, and up to 30 per cent die within 1 year after surgery. Early recurrences are related to aggressive tumours, probably associated with micrometastatic disease undetected at operation. There is therefore a need to identify more aggressive subtypes of PDAC in order to improve their management.

Ki-67 is a well known marker of cellular proliferation. Previous experience focusing on PDAC showed that high Ki-67 expression was associated with poor pathological features, including poor tumour differentiation and presence of lymph node metastasis.

The present study evaluated the prognostic role of Ki-67 in a series of 170 patients with PDAC and found that patients with a Ki-67 index above 50 per cent had median DFS and DSS approximately threefold lower than those with a Ki-67 index of 10 per cent or less (DFS: 8 versus 24 months respectively; DSS: 14 versus 47 months). In contrast, past reports showed no association between Ki-67 and overall survival, although Ki-67 index was associated with the risk of recurrence within 1 year after resection.

In the present study a strong association between Ki-67 index and tumour grade was also found. As expected, the combination of Ki-67 index above 50 per cent and G3 grade was associated with a greater risk of recurrence and poor survival.

The present results may have clinical implications for patients’ prognostic stratification. The Ki-67 index, as an expression of a more biologically unfavourable disease, might help to discriminate which patients should receive more aggressive adjuvant treatment. Currently, neoadjuvant chemotherapy is recommended for patients with anatomically borderline resectable pancreatic cancer at increased risk of early recurrence. Preoperative assessment of the Ki-67 index by EUS–FNA may help to identify patients with marginally resectable tumours based on clinical criteria, who may benefit more from neoadjuvant chemotherapy than upfront surgery, given the high risk of early postoperative recurrence (those with a Ki-67 index above 50 per cent), although the feasibility of this should be investigated further.

Limitations of this study include its retrospective design and some issues relating to Ki-67 analysis, including intratumoral and intertumoral heterogeneity. In addition, the immunohistochemistry protocol may have involved some interobserver variability in determining the percentage of Ki-67-positive cells. To limit the lack of uniformity and consistency in quantification, several imaging methods have been developed to be used in routine practice. However, standardization is needed to enable wider use of the index. Further investigations in larger cohorts are needed to validate these results.
Acknowledgements

I.P. and S.C. contributed equally to this paper.

Disclosure: The authors declare no conflict of interest.

References

1 Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreatic cancers in the United States. Cancer Res 2014; 74: 2913–2921.

2 Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingers MC et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016; 531: 47–52.

3 Myoteri D, Dellaportas D, Lykoudis PM, Apostolopoulos A, Marinis A, Zizi-Sermpetzoglou A. Prognostic evaluation of vimentin expression in correlation with Ki67 and CD44 in surgically resected pancreatic ductal adenocarcinoma. Gastroenterol Res Pract 2017; 2017: 9207616.

4 Goggins M. Markers of pancreatic cancer: working toward early detection. Clin Cancer Res 2011; 17: 635–637.

5 Sohal DP, Walsh RM, Ramanathan RK, Khorana AA. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J Natl Cancer Inst 2014; 106: dju011.

6 Jalava P, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P, Collan Y. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroup forming on Ki67 immunoreactivity and standardized mitotic index. Histopathology 2006; 48: 674–682.

7 Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311–322.

8 de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbeq V et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer 2007; 96: 1504–1513.

9 Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell’Orto P et al.; Breast International Group Trial 1-98. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26: 5569–5575.

10 Aaltomaa S, Kärjä V, Lipponen P, Isotalo T, Kankunen JP, Talja M et al. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. Anticancer Res 2006; 26: 4873–4878.

11 Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010; 23: 824–833.

12 Klöppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch 2018; 472: 341–349.

13 Crippa S, Partelli S, Belfiori G, Palucci M, Muffatti F, Adamenko O et al. Management of neuroendocrine carcinomas of the pancreas (WHO G3): a tailored approach between proliferation and morphology. World J Gastroenterol 2016; 22: 9944–9953.

14 Boninsegna L, Panzuto F, Partelli S, Capelli P, Delle Fave G, Bettini R et al. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer 2012; 48: 1608–1615.

15 Falconi M, Eriksson B, Kaltzas G, Bartsch DK, Capdevila J, Caplin M et al.; all other Vienna Consensus Conference participants. Consensus guidelines update for the management of functional p-NETs (F-p-NETs) and non-functional p-NETs (NF-p-NETs). Neuroendocrinology 2016; 103: 153–171.

16 Lloyd R, Osamura RY, Klöppel G, Rosai J. WHO Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs (4th edn). IARC: Lyons, 2017.

17 Larghi A, Caporuso G, Carmuccio A, Ricci R, Alfieri S, Galasso D et al. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study. Gastrointest Endosc 2012; 76: 570–577.

18 Hasegawa T, Yamao K, Hijikoa S, Bhatia V, Mizuno N, Harr K et al. Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors. Endoscopy 2014; 46: 32–38.

19 Farrell JM, Pang JC, Kim GE, Tabatabai ZL. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria. Cancer Cytopathol 2014; 122: 770–777.

20 Weynand B, Borbath I, Bernard V, Sempoux C, Gigot JF, Hubert C et al. Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: high reproducibility and inter-observer agreement of the Ki-67 labelling index. Cytopathology 2014; 25: 389–395.

21 Stanton KJ, Sidner RA, Miller GA, Cummings OW, Schmidt CM, Howard TJ et al. Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. Am J Surg 2003; 186: 486–492.

22 Hu HY, Liu H, Zhang JW, Hu K, Lin Y. Clinical significance of Smac and Ki-67 expression in pancreatic cancer. Hepatogastroenterology 2012; 59: 2640–2643.

23 Kim H, Park CY, Lee JH, Kim JC, Cho CK, Kim HJ. Ki-67 and p53 expression as a predictive marker for early postoperative recurrence in pancreatic head cancer. Ann Surg Treat Res 2015; 88: 200–207.

24 Altmann DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic...
studies (REMARK): explanation and elaboration. *PLoS Med* 2012; 9: e1001216.

25 von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Int J Surg* 2014; 12: 1495–1499.

26 Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A. *AJCC Cancer Staging Manual* (7th edn). Springer: New York, 2010.

27 Adsay NV, Fukushima N, Furukawa T, Hruhan RH, Klimstra DS, Klöppel G *et al.* *WHO Classification of Tumors of the Digestive System*. WHO Press: Lyons, 2010.

28 Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA *et al.* Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. *Ann Surg* 2018 Mar 23. doi: 10.1097/SLA.0000000000002734 [Epub ahead of print]

29 Barugola G, Partelli S, Marcucci S, Sartori N, Capelli P, Bassi C *et al.* Resectable pancreatic cancer: who really benefits from resection? *Ann Surg Oncol* 2009; 16: 3316–3322.

30 Sohal DPS, Willingham FF, Falconi M, Raphael KL, Crippa S. Pancreatic adenocarcinoma: improving prevention and survivorship. *Am Soc Clin Oncol Educ Book* 2017; 37: 301–310.

31 Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. *Lancet* 2016; 388: 73–85.

32 Isaji S, Mizuno S, Windsor JA, Bassi C, Fernández-del Castillo C, Hackert T *et al.* International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. *Pancreatology* 2018; 18: 2–11.

33 Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB *et al.* Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. *J Am Coll Surg* 2008; 206: 833–846.

34 Adsay V. Ki67 labeling index in neuroendocrine tumors of the gastrointestinal and pancreatobiliary tract: to count or not to count is not the question, but rather how to count. *Am J Surg Pathol* 2012; 36: 1743–1746.

---

**Supporting information**

Additional supporting information can be found online in the Supporting Information section at the end of the article.